ClinicalTrials.gg
RecruitingNCT05617027tDCS-painUpdated Mar 4, 2025

Relieving Chronic Pain in Older Adults With Transcranial Direct Current Stimulation

An interventional study of actual transcranial direct current stimulation (tDCS) and placebo transcranial direct current stimulation (tDCS) in Pain, Chronic, sponsored by Université de Sherbrooke. Recruiting at 3 sites in Canada. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Chronic Pain by Université de Sherbrooke — 8 open to participants now, 9 under way, none of them phase 3. Chronic Pain · Université de Sherbrooke.

Planned enrollment
Largest of 11
150 · median 32
Started
2023
with 1 other
No phase
10 of 15
7 open now
Registered
12th of 15
by date

Among the 15 studies in Chronic Pain by Université de Sherbrooke, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2023, is one of 10 with no phase, and was the 12th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

8 of the 15 studies in Chronic Pain by Université de Sherbrooke are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Chronic Pain by Université de Sherbrooke, or all of them as a file.
02

Study summary

The primary objective of this study is to determine, in a healthcare setting, the effectiveness of actual tDCS in reducing pain compared with placebo tDCS. This is a multicenter randomized controlled trial with parallel groups (real tDCS vs. placebo) blinded to participants, assessors and tDCS providers. The real tDCS group will receive a daily 20-minute session of tDCS (current intensity = 2 mA), for 5 consecutive days, while the placebo tDCS group will receive an equivalent treatment, but the current will be stopped after the first 30 seconds. The study will take place in 5 rehabilitation clinics in 3 Quebec regions. One hundred and fifty (150) seniors aged 65 years or older with chronic (> 6 months), moderate to severe musculoskeletal pain will be recruited (50 participants/region). Follow-ups will take place at 1 week and 3 months post-treatment. The primary dependent variable is pain intensity (numerical scale from 0 to 10). Secondary variables will be measured using standardized and validated questionnaires: 1) pain-related interferences (physical function, mood, quality of life) and 2) perception of post-TDCS changes. Neurophysiological measures (pain control pathways).

Read the detailed description

Rationale : Chronic pain is the leading cause of disability and affects a large number of seniors. Transcranial direct current stimulation (tDCS), which provides non-invasive stimulation of the brain, is a promising avenue for relieving pain that is refractory to traditional treatments. To date, however, its clinical efficacy has yet to be confirmed in the elderly.

Objectives : The primary objective of this study is to determine, in a healthcare setting, the effectiveness of actual tDCS in reducing pain compared with placebo tDCS. Secondary objectives are to assess the effect of tDCS on pain-related interference and the relationship between the response to tDCS and the integrity of pain control systems (descending pathways controlling pain circuits).

Methods : This is a multicenter randomized controlled trial with parallel groups (real tDCS vs. placebo) blinded to participants, assessors and tDCS providers. The real tDCS group will receive a daily 20-minute session of tDCS (current intensity = 2 mA), for 5 consecutive days, while the placebo tDCS group will receive an equivalent treatment, but the current will be stopped after the first 30 seconds. The study will take place in 5 rehabilitation clinics in 3 Quebec regions: Sherbrooke (n=1), Quebec City (n=2), Montreal (n=2). One hundred and fifty (150) seniors aged 65 years or older with chronic (> 6 months), moderate to severe musculoskeletal pain will be recruited (50 participants/region). Follow-ups will take place at 1 week and 3 months post-treatment. The primary dependent variable is pain intensity (numerical scale from 0 to 10). Secondary variables will be measured using standardized and validated questionnaires: 1) pain-related interferences (physical function, mood, quality of life) and 2) perception of post-TDCS changes. Neurophysiological measures (pain control pathways), i.e., the integrity of corticothalamic and corticospinal projections will be tested by diffusion MRI and transcranial magnetic stimulation.

Anticipated results: Our hypotheses are that (i) real tDCS will be more effective in reducing pain intensity than placebo tDCS at 1 week post-treatment. This reduction in pain will be maintained at the 3-month post-treatment follow-up of real tDCS. (ii) Real tDCS will be more effective than placebo treatment in reducing pain interference with physical function, mood and quality of life. Perceived improvement with the treatment received will also be greater for real tDCS. (iii) Individuals with stronger cortico-thalamic and corticospinal projections in pre-tDCS will be more relieved by actual tDCS than those with less strong projections.

Ultimately, this study will allow us to evaluate the effectiveness of tDCS in the care setting for the relief of chronic musculoskeletal pain in the elderly and to identify those individuals most likely to respond to this type of treatment based on potential biomarkers related to the integrity of the pain control system.

03

Conditions studied

  • Pain, Chronic

Browse trials for

Keywords

  • Chronic pain
  • transcranial direct current stimulation
  • quality of life
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be aged ≥ 65 years
  • Have chronic (≥ 6 months) musculoskeletal pain of moderate to severe intensity (≥4 out of 10 on a numerical scale of 0 to 10)

Exclusion criteria

Exclusion Criteria:

  • Those with to tDCS
  • Those with contraindications to TMS
  • Those with contraindications to IRM
  • Individuals for whom the procedure could cause impairment of well-being, or has another medical condition that could put them at risk in the judgment of a health care professional.
  • Patients taking medications that act on the GABAergic and glutamatergic systems (modulating tDCS effects) will be excluded
  • Individuals taking other types of medications or receiving rehabilitation are not excluded but will be asked, in the absence of clinical contraindication, to avoid any modification (e.g., new treatment, discontinuation, or change in dose) during the study.
  • People with epilepsy and seizures will not be excluded from the study. The research team will simply be asked to pay closer attention to these participants during the administration of MST.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    actual tDCS

    The actual transcranial direct current stimulation (tDCS) intervention will be conducted by a physiotherapist who will perform 5 sessions of actual tDCS , 5 consecutive days, for 20 minutes of treatment for a total of 45 minutes at the clinic for each session. The tDCS current will be 2 mA for the whole 20-minute session.

    Other: actual transcranial direct current stimulation (tDCS)

  • Placebo comparator
    placebo tDCS

    The placebo transcranial direct current stimulation (tDCS) intervention will be conducted by a physiotherapist who will perform 5 sessions of placebo tDCS, 5 consecutive days, for 20 minutes of treatment for a total of 45 minutes at the clinic for each session. The tDCS current will be 2 mA for 30 secondes, and then will strop for the rest of the 20-minute session (programming of the equipment).

    Other: placebo transcranial direct current stimulation (tDCS)

Interventions

  • Otheractual transcranial direct current stimulation (tDCS)

    tDCS is a non-invasive brain stimulation technique that would influence the brain's pain control mechanisms. The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA.

  • Otherplacebo transcranial direct current stimulation (tDCS)

    The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA for 30 secondes, and then 0 mA for the rest of the 20-minute session.

06

What researchers measure

Primary outcomes

  1. Change in pain intensity from baseline to 1 week after the intervention

    Visual analogue scale (0-10) where 0 = no pain, 10= worst pain

    Time frame: Mean of Patient reported pain on 5 consecutive days: i. 1 week before the intervention compared to1 week after the intervention

  2. Maintenance of the effect on pain after from to 1 week to 3 months after intervention

    Visual analogue scale (0-10) where 0 = no pain, 10= worst pain

    Time frame: Mean of Patient reported pain on 5 consecutive days: 3 months after the intervention to see if the effect of the treatment is maintained.

Secondary outcomes

  1. Sociodemographic, life habits, and medical history data

    Questionnaire including questions regarding age, sex, gender, education, salary, drug use, coffee, tobacco, alcohol, diagnosis, time since onset of symptoms, concomitant medication.

    Time frame: Selection visit (pre-intervention)

  2. Change in affective component of pain from baseline to 1 week and 3 months after intervention

    McGill-Melzack Questionnaire: The 20 questions in this tool focus on the qualitative aspect of pain, for a total of 78 points, and are divided into 4 subcategories: sensory, affective, evaluative and miscellaneous. Higher is the score, the greater is the pain.

    Time frame: i. 1 week before the intervention, ii. 1 week after the intervention, and iii. 3 months after the intervention

  3. Change in mood from baseline to 1 week and 3 months after intervention

    Hospital Anxiety and Depression Scale (HADS): 14-item questionnaire measured with a 4-point Likert scale (0 = no to 3 = yes, definitively). Higher score indicating higher distress.

    Time frame: i. 1 week before the intervention, ii. 1 week after the intervention, and iii. 3 months after the intervention

  4. Change in physical function related to pain from baseline to 1 week and 3 months after intervention

    Brief Pain Inventory - short form (BPI): this 9 item questionnaire is use to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. It uses a 0 to 10 numeric rating scales for item rating. The BPI has no scoring algorithm.

    Time frame: i. 1 week before the intervention, ii. 1 week after the intervention, and iii. 3 months after the intervention

  5. Change in quality of life covering eight domains of health from baseline to 1 week and 3 months after intervention

    36-Item Short Form Survey (SF-36): This questionnaire covers eight domains of health related to quality of life: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. A high score defines a more favorable health state.

    Time frame: i. 1 week before the intervention, ii. 1 week after the intervention, and iii. 3 months after the intervention

  6. Change in perception of change with treatment from 1 week to 3 months after intervention

    Patient Global Impression of Change (PGIC). This questionnaire assesses perceived changes using a 7-point scale, ranging from "Significantly Worsened" to "Significantly Improved.

    Time frame: i. 1 week after the intervention, and ii. 3 months after the intervention

  7. Neurophysiological measures (MRI, Tractography)

    Magnetic resonance imaging (MRI) is an imaging test that uses powerful magnetic forces, radio waves and a computer to produce detailed 3-dimensional images of organs, bones and soft tissue inside your body. In this particular context, IRM will allow to quantify the integrity and morphology of myelinated corticospinal projection (in the brain) via a diffusion MRI and mathematical reconstruction of the tract (tractography analysis).

    Time frame: i. 1 week before the intervention

  8. Functional neuroanatomical measurement (TMS)

    Transcranial Magnetic Stimulation (TMS): allows the evaluation of corticospinal projections. This technique aims to stimulate certain nerve cells via short magnetic pulses directed to the brain.This stimulation release a potential.known as a motor evoked potential, MEP which is then recorded using electromyography (EMG). The magnitude of muscle activity generated for a given TMS pulse strength forms a measure of cortical excitability in the stimulated region.

    Time frame: i. 1 week before the intervention

07

Study locations

3 of 3 sites recruiting
  • Institut universitaire sur la réadaptation en déficience physique de Montréal (IURDPM)
    Montréal, Quebec H3S 2J4, Canada
    Recruiting
  • CHU de Québec-Université Laval
    Québec, Quebec G1V 4G2, Canada
    Recruiting
  • Centre de recherche sur le vieillissement (CdRV)
    Sherbrooke, Quebec J1H 4C4, Canada
    Recruiting
    • Marie-Philippe Harvey, Ph.D. · Contactmarie.philippe.harvey@usherbrooke.ca · 819-821-8000
    • Guillaume Leonard, Ph.D., pht. · Contact819-821-8000
    • Guillaume Leonard · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for May 2025, 18 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 18 months is close to that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2022
First posted
Nov 15, 2022
StartActual
Oct 19, 2023
Primary completionEst.
May 15, 2025
CompletionEst.
Jun 1, 2025
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05617027
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Nov 15, 2022
Start date
Oct 19, 2023
Primary completion
May 15, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Mar 4, 2025

Study contacts

Marie-Philippe Harvey, Ph. D
Contact
marie.philippe.harvey@usherbrooke.ca
819 821-8000 ext. 45082
Guillaume Léonard, Ph. D
Contact
guillaume.leonard2@usherbrooke.ca
819-780-2220 ext. 72933
Guillume Léonard
principal investigator · Université de Sherbrooke

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion